The Disease Interception Accelerator established a partnership with UbiVac, a privately held, clinical-stage, immuno-oncology company for the development of an immunotherapy that is intended to intercept oral cavity/oropharyngeal cancer.
Collaborating in more than 150 markets.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen.com.
These sections or websites are governed by their own Legal and Privacy Policies.
Europe, Middle East & Africa (EMEA)
Oral Cavity Oropharyngeal Cancer
Partnership to Intercept Oral Cavity/Oropharyngeal Cancer